NASDAQ
2.73USD
-0.04 (-1.62%)
We have scored 3 news catalysts on Anixa Biosciences, Inc. (ANIX) over the past 12 months. The biggest single-day move next to one of them came Apr 1, 2026, when ANIX closed +5.4%: “Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing”. Coverage across the window leans positive (average ticker sentiment +0.87). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
92.5M
P/E
—
EPS
—
Beta
0.60
52W range
2.32-5.46
Day range
2.68–2.82
Open
2.82
Prev close
2.77
Volume
128.5K
Avg volume
253.6K
Dividend
0.00
IPO
1983-10-07
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Anixa Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ANIX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
